|
|
Decreased levels of CSF A Beta 40 and A Beta 42 occur before HCHWA-D mutation carriers develop clinical symptoms, implicating vascular deposition of both A Beta species as early steps in cerebral amyloid angiography pathogenesis. CSF A Beta 40 and A Beta 42 may serve as preclinical biomarkers of cerebral amyloid angiography pathology. |
|